Literature DB >> 9063373

Activated T cells and cytokine-induced CD3+CD56+ killer cells.

G D Schmidt-Wolf1, R S Negrin, I G Schmidt-Wolf.   

Abstract

Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9063373     DOI： 10.1007/s002770050257

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  34 in total

1.  Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells.

Authors:  Catharina Gross; Ingo G H Schmidt-Wolf; Srinivas Nagaraj; Robert Gastpar; Joachim Ellwart; Leoni A Kunz-Schughart; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

2.  Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme.

Authors:  Prachya Vichchatorn; Adisak Wongkajornsilp; Sawang Petvises; Sumalee Tangpradabkul; Samart Pakakasama; Suradej Hongeng
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 3.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

4.  Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.

Authors:  Yohei Mineharu; Neha Kamran; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Cancer Ther       Date:  2014-09-25       Impact factor: 6.261

Review 5.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

6.  Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia.

Authors:  Hong Wang; Fenglin Cao; Jinmei Li; Yong Li; Xiuhua Liu; Lifan Wang; Zhiyu Liu; Yang Li; Hui Zhao; Jin Zhou
Journal:  Int J Hematol       Date:  2014-06-15       Impact factor: 2.490

7.  Cytotoxicity of rat marrow stromal cells against malignant glioma cells.

Authors:  Seok-Gu Kang; Sin Soo Jeun; Jung Yeon Lim; Do Sung Yoo; Pil Woo Huh; Kyung Souk Cho; Dal Soo Kim; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2005-06-03       Impact factor: 1.475

8.  Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Fu-Sheng Wang; Ming-Xu Liu; Bing Zhang; Ming Shi; Zhou-Yun Lei; Wen-Bing Sun; Qing-You Du; Ju-Mei Chen
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

9.  Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.

Authors:  Xiao-Hui Du; Hai-Liang Liu; Li Li; Shao-You Xia; Ning Ning; Zhen-Yu Zou; Da Teng; Chun-Hong Xiao; Rong Li; Ying-Xin Xu
Journal:  Tumour Biol       Date:  2015-03-13

10.  CD4+T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation.

Authors:  Jinpu Yu; Weihong Zhang; Huawei Jiang; Hui Li; Shui Cao; Xinbao Ren
Journal:  Cancer Biother Radiopharm       Date:  2008-06       Impact factor: 3.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.